Summary of evidence and guidelines for treatment of acute VTE in the thrombocytopenic cancer patient. Recommendations for each anticoagulant and platelet thresholds are based on published consensus guidelines or major published trials and studies. For patients that cannot be transfused, timing of onset and severity of VTE must be considered. ^aHigh risk for thrombus propagation is defined as acute proximal or recurrent thrombosis. ^bDabigatran is not displayed as an option because of the lack of data, studies, or discussion in guideline statements. ^cThe ISTH and NCCN guidelines recommend holding anticoagulation at platelet counts of <25 000/µL, whereas the ASCO guidelines use a threshold of 20 000/µL. ^dLow-dose LMWH is generally defined as prophylactic dosing (eg, 30-40 mg enoxaparin daily or 5000 U dalteparin daily), and intermediate-dose LMWH is variably defined as enoxaparin 0.5 mg/kg twice daily or 1 mg/kg once daily (Table 2). ^eDefined in this study as rivaroxaban 10 mg twice daily during the first 3 weeks of treatment or 10 mg once daily after the first 3 weeks of treatment.³  Plt, platelet count.